What the Study Found
A large observational study published in 'The Lancet Regional Health Europe' examined the health records of over 80,000 people with Type 2 diabetes in Italy. It found that patients who stopped taking GLP-1 receptor agonists (GLP-1s) had approximately
double the risk of a major cardiovascular event—defined as a non-fatal heart attack, a non-fatal stroke, or death from any cause—compared to those who continued the treatment. The rate of these events was about four per 100 people per year in the group that stopped, versus about two per 100 people in the group that continued their medication. Notably, the study also found that the risk was even more pronounced in patients with obesity.
The Crucial 'Association' Versus 'Causation' Debate
This is the most critical point to understand. The study shows an association, or a link, but it does not prove that stopping the drug directly causes heart attacks or strokes. Because it was an observational study, researchers looked back at patient data rather than conducting a controlled experiment. This means other factors could be at play. For example, patients who are sicker or have other underlying health problems might be more likely to stop their medication, and those same health problems could be what increases their cardiovascular risk. As one expert noted, the takeaway is not that stopping the drug causes the event, but that continuing the drug is what provides the protection.
Why Might Risk Increase After Stopping?
Experts believe the loss of the drug's protective benefits is the primary driver. GLP-1s do more than just facilitate weight loss; they help regulate blood sugar, reduce inflammation, and have known cardiovascular benefits. When treatment stops, these protective effects cease. The body can experience a 'rebound' effect. Appetite and cravings return, often leading to weight regain. Blood pressure, cholesterol, and blood sugar levels, which were controlled by the medication, can worsen. This return to a higher-risk cardiometabolic state is believed to be the main reason for the increased association with adverse events, rather than the act of stopping itself causing some new harm.
Who Was in the Study and What Are the Limits?
The study focused specifically on patients with Type 2 diabetes who had no prior history of major cardiovascular events. A very high percentage of participants, around 60%, had discontinued their medication. It is important to note that the findings may not apply to people taking these drugs solely for weight loss without having diabetes. The study's authors were careful to point out its limitations, including that they did not know the specific reasons why individuals stopped treatment. Cost, side effects like nausea and vomiting, or supply shortages are all common reasons for discontinuation.
What Should Patients in India Do?
The rise of GLP-1s for managing diabetes and, increasingly, for weight management, is a global phenomenon with growing relevance in India. The key message from this study is not to panic, but to be informed. If you are taking a GLP-1 medication, it's crucial not to stop it abruptly or without medical guidance. These are intended as long-term treatments for chronic conditions like diabetes and obesity. If you are experiencing side effects, concerned about cost, or thinking about stopping for any reason, the first and most important step is to have a detailed conversation with your doctor. There may be alternative medications or strategies to manage your condition effectively.
















